FasL :Fas ratio-A prognostic factor in breast carcinomas
Programmed cell death (apoptosis) is primarily mediated by Fas ligand (FasL; CD95L) and the Fas receptor (Fas; CD95). In this study, FasL was detected by immunohistochemical analysis in 85% of breast carcinomas and 14% of fibroadenomas randomly chosen, indicating that high expression of FasL might p...
Gespeichert in:
| Veröffentlicht in: | Cancer research (Chicago, Ill.) Ill.), 2000-02, Vol.60 (4), p.822-828 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 828 |
|---|---|
| container_issue | 4 |
| container_start_page | 822 |
| container_title | Cancer research (Chicago, Ill.) |
| container_volume | 60 |
| creator | REIMER, T HERRNRING, C KOCZAN, D RICHTER, D GERBER, B KABELITZ, D FRIESE, K THIESEN, H.-J |
| description | Programmed cell death (apoptosis) is primarily mediated by Fas ligand (FasL; CD95L) and the Fas receptor (Fas; CD95). In this study, FasL was detected by immunohistochemical analysis in 85% of breast carcinomas and 14% of fibroadenomas randomly chosen, indicating that high expression of FasL might play a role in tumor pathology. FasL and Fas levels as well as FasL:Fas ratios were further ascertained in 215 human breast tumors, including 199 invasive ductal carcinomas, by real-time quantitative reverse transcription-PCR and compared with expression levels and ratios found in 25 normal human tissues, in 37 fibroadenomas, and in 5 normal breast tissues. Among breast carcinomas, high FasL mRNA expression seems to be positively correlated with histological grading (n = 212; P1 is found to be significantly associated with decreased patient's disease-free survival (n = 211; P1 is related to tumor progression scored by histological grading (n = 212; P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70938209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70938209</sourcerecordid><originalsourceid>FETCH-LOGICAL-h268t-3bcf35e1089a53d844571ab0753bf91b3c7aa116053c322677e95d74830146123</originalsourceid><addsrcrecordid>eNpFj09LxDAUxIMobq1-BclBvAVe-pom9bYs7ioUvOi5vKapRvpnTdqD396CK15mGPgxzJyxRCo0Que5OmcJABihcp1t2FWMn2tUEtQl20jQUIDRCTN7ihV_WJUHmv0ktvwYpvdxirO3vCM7T4H7kTfBUZy5pWD9OA0Ur9lFR310NydP2dv-8XX3JKqXw_NuW4mPrDCzwMZ2qJwEU5LC1qzDtKQGtMKmK2WDVhNJWYBCi1lWaO1K1ercIMi8kBmm7P63d531tbg414OP1vU9jW5aYq2hRJOtkrLbE7g0g2vrY_ADhe_67-sK3J0Aipb6LtBoffznEFEawB9GH1q4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70938209</pqid></control><display><type>article</type><title>FasL :Fas ratio-A prognostic factor in breast carcinomas</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>REIMER, T ; HERRNRING, C ; KOCZAN, D ; RICHTER, D ; GERBER, B ; KABELITZ, D ; FRIESE, K ; THIESEN, H.-J</creator><creatorcontrib>REIMER, T ; HERRNRING, C ; KOCZAN, D ; RICHTER, D ; GERBER, B ; KABELITZ, D ; FRIESE, K ; THIESEN, H.-J</creatorcontrib><description>Programmed cell death (apoptosis) is primarily mediated by Fas ligand (FasL; CD95L) and the Fas receptor (Fas; CD95). In this study, FasL was detected by immunohistochemical analysis in 85% of breast carcinomas and 14% of fibroadenomas randomly chosen, indicating that high expression of FasL might play a role in tumor pathology. FasL and Fas levels as well as FasL:Fas ratios were further ascertained in 215 human breast tumors, including 199 invasive ductal carcinomas, by real-time quantitative reverse transcription-PCR and compared with expression levels and ratios found in 25 normal human tissues, in 37 fibroadenomas, and in 5 normal breast tissues. Among breast carcinomas, high FasL mRNA expression seems to be positively correlated with histological grading (n = 212; P<0.0001). A ratio of FasL:Fas mRNA transcripts >1 is found to be significantly associated with decreased patient's disease-free survival (n = 211; P<0.03) and increased mortality (n = 211; P = 0.19). A FasL:Fas ratio >1 is related to tumor progression scored by histological grading (n = 212; P<0.02). The selection process leading to highly aggressive breast tumor variants might be enhanced by FasL-mediated tumor fratricide, eventually a possible target for novel therapeutic strategies.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 10706087</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Breast Neoplasms - chemistry ; Breast Neoplasms - pathology ; Fas Ligand Protein ; fas Receptor - analysis ; fas Receptor - genetics ; Female ; Fibroadenoma - chemistry ; Fibroadenoma - pathology ; Gene Dosage ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; Male ; Mammary gland diseases ; Medical sciences ; Membrane Glycoproteins - analysis ; Membrane Glycoproteins - genetics ; Middle Aged ; Prognosis ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - analysis ; Tumors</subject><ispartof>Cancer research (Chicago, Ill.), 2000-02, Vol.60 (4), p.822-828</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1333180$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10706087$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>REIMER, T</creatorcontrib><creatorcontrib>HERRNRING, C</creatorcontrib><creatorcontrib>KOCZAN, D</creatorcontrib><creatorcontrib>RICHTER, D</creatorcontrib><creatorcontrib>GERBER, B</creatorcontrib><creatorcontrib>KABELITZ, D</creatorcontrib><creatorcontrib>FRIESE, K</creatorcontrib><creatorcontrib>THIESEN, H.-J</creatorcontrib><title>FasL :Fas ratio-A prognostic factor in breast carcinomas</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Programmed cell death (apoptosis) is primarily mediated by Fas ligand (FasL; CD95L) and the Fas receptor (Fas; CD95). In this study, FasL was detected by immunohistochemical analysis in 85% of breast carcinomas and 14% of fibroadenomas randomly chosen, indicating that high expression of FasL might play a role in tumor pathology. FasL and Fas levels as well as FasL:Fas ratios were further ascertained in 215 human breast tumors, including 199 invasive ductal carcinomas, by real-time quantitative reverse transcription-PCR and compared with expression levels and ratios found in 25 normal human tissues, in 37 fibroadenomas, and in 5 normal breast tissues. Among breast carcinomas, high FasL mRNA expression seems to be positively correlated with histological grading (n = 212; P<0.0001). A ratio of FasL:Fas mRNA transcripts >1 is found to be significantly associated with decreased patient's disease-free survival (n = 211; P<0.03) and increased mortality (n = 211; P = 0.19). A FasL:Fas ratio >1 is related to tumor progression scored by histological grading (n = 212; P<0.02). The selection process leading to highly aggressive breast tumor variants might be enhanced by FasL-mediated tumor fratricide, eventually a possible target for novel therapeutic strategies.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - pathology</subject><subject>Fas Ligand Protein</subject><subject>fas Receptor - analysis</subject><subject>fas Receptor - genetics</subject><subject>Female</subject><subject>Fibroadenoma - chemistry</subject><subject>Fibroadenoma - pathology</subject><subject>Gene Dosage</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - analysis</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Messenger - analysis</subject><subject>Tumors</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFj09LxDAUxIMobq1-BclBvAVe-pom9bYs7ioUvOi5vKapRvpnTdqD396CK15mGPgxzJyxRCo0Que5OmcJABihcp1t2FWMn2tUEtQl20jQUIDRCTN7ihV_WJUHmv0ktvwYpvdxirO3vCM7T4H7kTfBUZy5pWD9OA0Ur9lFR310NydP2dv-8XX3JKqXw_NuW4mPrDCzwMZ2qJwEU5LC1qzDtKQGtMKmK2WDVhNJWYBCi1lWaO1K1ercIMi8kBmm7P63d531tbg414OP1vU9jW5aYq2hRJOtkrLbE7g0g2vrY_ADhe_67-sK3J0Aipb6LtBoffznEFEawB9GH1q4</recordid><startdate>20000215</startdate><enddate>20000215</enddate><creator>REIMER, T</creator><creator>HERRNRING, C</creator><creator>KOCZAN, D</creator><creator>RICHTER, D</creator><creator>GERBER, B</creator><creator>KABELITZ, D</creator><creator>FRIESE, K</creator><creator>THIESEN, H.-J</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20000215</creationdate><title>FasL :Fas ratio-A prognostic factor in breast carcinomas</title><author>REIMER, T ; HERRNRING, C ; KOCZAN, D ; RICHTER, D ; GERBER, B ; KABELITZ, D ; FRIESE, K ; THIESEN, H.-J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h268t-3bcf35e1089a53d844571ab0753bf91b3c7aa116053c322677e95d74830146123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - pathology</topic><topic>Fas Ligand Protein</topic><topic>fas Receptor - analysis</topic><topic>fas Receptor - genetics</topic><topic>Female</topic><topic>Fibroadenoma - chemistry</topic><topic>Fibroadenoma - pathology</topic><topic>Gene Dosage</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - analysis</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Messenger - analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>REIMER, T</creatorcontrib><creatorcontrib>HERRNRING, C</creatorcontrib><creatorcontrib>KOCZAN, D</creatorcontrib><creatorcontrib>RICHTER, D</creatorcontrib><creatorcontrib>GERBER, B</creatorcontrib><creatorcontrib>KABELITZ, D</creatorcontrib><creatorcontrib>FRIESE, K</creatorcontrib><creatorcontrib>THIESEN, H.-J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>REIMER, T</au><au>HERRNRING, C</au><au>KOCZAN, D</au><au>RICHTER, D</au><au>GERBER, B</au><au>KABELITZ, D</au><au>FRIESE, K</au><au>THIESEN, H.-J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FasL :Fas ratio-A prognostic factor in breast carcinomas</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2000-02-15</date><risdate>2000</risdate><volume>60</volume><issue>4</issue><spage>822</spage><epage>828</epage><pages>822-828</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Programmed cell death (apoptosis) is primarily mediated by Fas ligand (FasL; CD95L) and the Fas receptor (Fas; CD95). In this study, FasL was detected by immunohistochemical analysis in 85% of breast carcinomas and 14% of fibroadenomas randomly chosen, indicating that high expression of FasL might play a role in tumor pathology. FasL and Fas levels as well as FasL:Fas ratios were further ascertained in 215 human breast tumors, including 199 invasive ductal carcinomas, by real-time quantitative reverse transcription-PCR and compared with expression levels and ratios found in 25 normal human tissues, in 37 fibroadenomas, and in 5 normal breast tissues. Among breast carcinomas, high FasL mRNA expression seems to be positively correlated with histological grading (n = 212; P<0.0001). A ratio of FasL:Fas mRNA transcripts >1 is found to be significantly associated with decreased patient's disease-free survival (n = 211; P<0.03) and increased mortality (n = 211; P = 0.19). A FasL:Fas ratio >1 is related to tumor progression scored by histological grading (n = 212; P<0.02). The selection process leading to highly aggressive breast tumor variants might be enhanced by FasL-mediated tumor fratricide, eventually a possible target for novel therapeutic strategies.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>10706087</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-5472 |
| ispartof | Cancer research (Chicago, Ill.), 2000-02, Vol.60 (4), p.822-828 |
| issn | 0008-5472 1538-7445 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70938209 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Aged Biological and medical sciences Breast Neoplasms - chemistry Breast Neoplasms - pathology Fas Ligand Protein fas Receptor - analysis fas Receptor - genetics Female Fibroadenoma - chemistry Fibroadenoma - pathology Gene Dosage Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Male Mammary gland diseases Medical sciences Membrane Glycoproteins - analysis Membrane Glycoproteins - genetics Middle Aged Prognosis Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - analysis Tumors |
| title | FasL :Fas ratio-A prognostic factor in breast carcinomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T01%3A01%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FasL%20:Fas%20ratio-A%20prognostic%20factor%20in%20breast%20carcinomas&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=REIMER,%20T&rft.date=2000-02-15&rft.volume=60&rft.issue=4&rft.spage=822&rft.epage=828&rft.pages=822-828&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70938209%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70938209&rft_id=info:pmid/10706087&rfr_iscdi=true |